VolitionRx

Overview
Price performance
Financials
Research
Sector insights
Thematics

VolitionRx is a clinical diagnostics company developing easy-to-use and cost-effective blood tests to diagnose a range of diseases in humans and animals including sepsis and cancer. Diagnostic Nu.Q tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid.

Latest Insights

Healthcare |
edison tv

15.02.24

VolitionRx webinar: Unravelling the web of NETs in sepsis … Part II

Healthcare |
Update

08.02.24

VolitionRx — Snaring sepsis, with early NETs detection

Healthcare |
edison tv

30.10.23

VolitionRx webinar: Breakthrough liquid biopsy method for cancer detection

Healthcare |
edison tv

03.05.23

Volition Webinar: Unraveling the web of NETs in sepsis

Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Managing Director - Head of Content, Healthcare

Jyoti Prakash

Analyst, Healthcare

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Key Management

Cameron Reynolds

CEO
Jake Micallef

Chief Scientific Officer
Scott Powell

Director of IR
Terig Hughes

CFO

Balance Sheet

Forecast net debt (US$m)

1.6

Forecast gearing ratio (%)

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(29.2)	(36.4)	(61.9)
Relative	(27.3)	(39.3)	(68.4)
52 week high/low	US$2.0/US$0.6

Financials

VolitionRx continues to make headway in growing a body of clinical evidence to build Nu.Q® NETs as a potential breakthrough tool in sepsis. These efforts, coupled with its CE mark in Europe, are a strong foundation in rapid and simplified sepsis detection that seeks to address the limitations and complexities of the current standard of care. Sepsis (immune-system triggered organ dysfunction) has a worrisome prevalence, affecting c 50 million per year with a mortality rate of c 20–25%, exceeding the combination of many leading cancers. Further, every hour of delayed treatment increases the chances of mortality of this preventable condition by c 8%. In this note we recap VolitionRx’s recent clinical updates, as we look forward to near-term improvements in early sepsis detection.